The U.S. Centers for Medicare & Medicaid Services has entered into agreements with Vertex Pharmaceuticals (blue‘>VRTX) and bluebird bio (BLUE) to help increase patient access to their gene therapies, Lyfgenia and Casgevy, Reuters’ Bhanvi Satija reports. The “outcomes-based agreements” will tie payments to whether the therapy improves health outcomes for patients who receive these drugs and are enrolled in government-backed Medicaid insurance plans, according to the report. The Vertex-CRISPR therapy has a U.S. list price of $2.2M, while bluebird’s is $3.1M.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on VRTX:
- CRISPR Therapeutics (NASDAQ:CRSP) Boasts Solid Potential and Limited Risk
- American upgraded, Regeneron initiated: Wall Street’s top analyst calls
- Vertex Pharmaceuticals initiated with a Buy at Citi
- Vertex Pharmaceuticals Faces Integration Challenges in Alpine Acquisition
- Vertex Pharmaceuticals price target raised to $408 from $361 at Canaccord
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
